Eric Hewitt, DO
Family Medicine · Avon, INNPI 1265531909
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,156 of the $5,109 with a category attached, or 61.8%. 37 manufacturers reported payments, led by Novo Nordisk AS at 36.2% of the total. Reporting peaked in 2019 at $3,048 and has fallen 95.8% since, to $128 in 2025.
Across 160 payments — averaging $31.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- Eli Lilly$644
- Novo Nordisk$482
- AbbVie$272
- AstraZeneca$240
- Exact Sciences$193
- plus $1K from 31 others
Across 1,068 payments — averaging $1596.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.2M
- Novo Nordisk AS$400K
- Ferring Pharmaceuticals AS$62K
- Ferring International Pharmascience Center US$18K
- GSK$8K
- Kowa Research Institute, Inc.$7K
What the payments were for
- Travel & lodging$1,92738%
- Food & beverage$3,15662%
- Education$261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,849 |
| Eli Lilly | 4 | $644 |
| Novo Nordisk | 31 | $482 |
| AbbVie(2 entities) | 16 | $272 |
| AstraZeneca | 12 | $240 |
| Exact Sciences | 11 | $193 |
| GSK | 6 | $170 |
| Lilly USA, LLC | 13 | $132 |
| Novartis | 8 | $117 |
| Biocompatibles, Inc. | 1 | $110 |
| Johnson & Johnson | 4 | $76 |
| Livanova USA, Inc. | 5 | $76 |
| Idorsia Pharmaceuticals US Inc | 1 | $74 |
| Dexcom, Inc. | 4 | $67 |
| Jazz Pharmaceuticals Inc. | 3 | $61 |
| Biogen | 3 | $51 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Acorda Therapeutics, Inc | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Pfizer | 3 | $38 |
| Sanofi | 2 | $30 |
| Eisai Inc. | 2 | $27 |
| UCB, Inc. | 2 | $26 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Shire North American Group Inc | 2 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Nalpropion Pharmaceuticals LLC | 1 | $21 |
| Amgen | 1 | $14 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,109 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $103,811 |
| EliquisApixaban | 94 | $79,357 |
| TrulicityDulaglutide | 48 | $57,536 |
| MounjaroTirzepatide | 53 | $56,759 |
| XareltoRivaroxaban | 37 | $32,250 |
| JardianceEmpagliflozin | 28 | $30,362 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 48 | $29,439 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $26,538 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $23,742 |
| EntrestoSacubitril/Valsartan | 12 | $21,163 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $18,682 |
| RybelsusSemaglutide | 14 | $16,610 |
| JanuviaSitagliptin Phosphate | 11 | $15,928 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 59 | $12,968 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 51 | $8,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $482 | $120,421110 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $132 | $114,295101 claims |
| PfizerEliquis | $38 | $79,35794 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Shingrix, Breo Ellipta, Arexvy | $170 | $73,820158 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $11 | $62,89962 claims |
| Johnson & JohnsonXarelto | $76 | $32,25037 claims |
| NovartisEntresto | $117 | $21,16312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Avon
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.